Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

23.80 +0.28 (+1.19%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Summit Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Why Summit Therapeutics Stock Is Soaring Again Today
This high-flying biotech stock is moving even higher -- and for good reason. 
Via The Motley Fool
Signet Jewelers Posts Better-Than-Expected Earnings, Joins NETGEAR, Lovesac And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
Summit Therapeutics, With 85% Gain This Week, Rockets Again On $235 Million Sale
The company is adding onto its success outperforming Merck's top drug in lung cancer patients. 
Via Investor's Business Daily
Summit Therapeutics Surges on Trial Results: Time to Buy?
Summit Therapeutics has surged almost 100% this week, driven by positive Phase III trial results for its cancer therapy Ivonescimab. 
Via MarketBeat
Why Summit Therapeutics (SMMT) Stock Is Rising Today
Summit Therapeutics shares are trading higher by 5.1% Thursday morning. The company announced it raised $235 million in net proceeds. 
Via Benzinga
Summit Therapeutics Options Trading: A Deep Dive into Market Sentiment
 
Via Benzinga
Summit Therapeutics Raises $235 Million
From Summit Therapeutics Inc.
Via Business Wire
Is Summit Therapeutics a Buy Now?
The clinical-stage drugmaker's cancer therapy candidate outperformed Keytruda, the world's top-selling cancer drug. 
Via The Motley Fool
Why Summit Therapeutics Rocketed Over 60% Today
The company's new lung cancer treatment could unseat Merck's Keytruda in the $50 billion-plus lung cancer treatment market. 
Via The Motley Fool
Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
Starbucks To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Monday
 
Via Benzinga
Biotech Stocks: Lung Cancer Treatment Outflanks Merck's Keytruda
Summit shares jumped Monday after positive late-stage indications vs. Merck's Keytruda. The biotech stock rallied 30%. 
Via Investor's Business Daily
Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half
Summit Therapeutics shared Phase 3 HARMONi-2 trial data of ivonescimab, showing significant improvement in progression-free survival compared to Merck's Keytruda in non-small cell lung cancer patients,... 
Via Benzinga
Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China
From Summit Therapeutics Inc.
Via Business Wire
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
HARMONi-2, Featuring Ivonescimab Monotherapy vs. Pembrolizumab Monotherapy, to be Showcased in Presidential Symposium at WCLC 2024
From Summit Therapeutics Inc.
Via Business Wire
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
SMMT Stock Earnings: Summit Therapeutics Beats EPS for Q2 2024
SMMT stock results show that Summit Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2024
From Summit Therapeutics Inc.
Via Business Wire
Summit Therapeutics to Host Second Quarter 2024 Financial Results & Operational Progress Call on August 6, 2024
From Summit Therapeutics Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Summit Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Development of Ivonescimab
From Summit Therapeutics Inc.
Via Business Wire
Stock Market News For July 23: Quick Takes On GE Aerospace, Boeing, Biotechs
What sectors outperformed after Trump won the 2016 election, and which outperformed during his term? 
Via Investor's Business Daily
Topics Government
IQVIA Posts Upbeat Earnings, Joins Terex, Reddit And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details
10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit... 
Via Benzinga
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
7 Top Stocks Under $10: June 2024 Edition
While blue-chip stocks are great, it's also a good idea to invest in top stocks under $10 to help improve your portfolio's diversification. 
Via InvestorPlace
3 Stocks That Have Soared 179% or More in 2024 and Could Go Even Higher, According to Wall Street
These high-flying stocks could have more room to run if analysts are right. 
Via The Motley Fool
Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million
Structure Therapeutics announced positive clinical results for its obesity drug, and then raised $476 million via an offering of its ADSs. Meanwhile, Alphamab Oncology announced a deal with ArriVent... 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.